Evidence map›Paper›PMID 40027940›Full record

ArticleThe journal of liquid biopsy2024

The role of liquid biopsy as a catalyst for sustained progress in precision oncology - Perspective of the young committee of the international society of liquid biopsy.

Erick F Saldanha, Eleonora Nicolo, Konstantinos Venetis, Diego de Miguel-Perez, Ana Ortega-Franco, Angelo Dipasquale, Mohamed A Gouda, Surbhi Singhal, George Adigbli, Carolina Reduzzi

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of liquid biopsy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Erick F SaldanhaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, ON, Canada.
Eleonora NicoloDepartment of Medicine, Weill Cornell Medicine, New York, NY, 10021, USA.
Konstantinos VenetisDivision of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Diego de Miguel-PerezCenter for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, 10029, NY, USA.
Ana Ortega-FrancoMedical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.
Angelo DipasqualeMedical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, (Milan), Italy.
Mohamed A GoudaDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX. 77030, USA.
Surbhi SinghalDivision of Hematology and Oncology, Department of Medicine, University of California Davis Comprehensive Cancer Centre, Sacramento, CA, USA.
George AdigbliTranslational Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, OX3 9DU, UK.
Carolina ReduzziDepartment of Medicine, Weill Cornell Medicine, New York, NY, 10021, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40027940
PMCPMC11863974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.